• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

IMS Purchases SDI

Quote








The temporary move to Collegeville is off?? Some crazy stuff going down. Nobody knew what was up with that. Speculation is poor second quarter for US business and IMS can't afford to make the move. The MAS division is doing particularly bad and losing people weekly.
 








Anonymous said:
Rumor on the outside is a deal is in the works.
Click to expand...

What did you expect? It's only been 8 months post SDI acquisition and the wheels on that business case are already falling off. Of course they need another acquisition to paper over the shortfall in the core business and the amazing service line organization structure.
 
























Seen the article last week in the FT on Cegedim? A case study on an IMS competitor and "proof" that aggressive, over-leveraged acquisitions in healthcare support/information services gives everyone a warm fuzzy feeling - either that or the MSM is warming the investing public up for an IMS acquisition/sale.
 
























Top Bottom
Back
Quote